DE69815518D1 - S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist - Google Patents

S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist

Info

Publication number
DE69815518D1
DE69815518D1 DE69815518T DE69815518T DE69815518D1 DE 69815518 D1 DE69815518 D1 DE 69815518D1 DE 69815518 T DE69815518 T DE 69815518T DE 69815518 T DE69815518 T DE 69815518T DE 69815518 D1 DE69815518 D1 DE 69815518D1
Authority
DE
Germany
Prior art keywords
mpec
cinnamanilide
piperidyl
ethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69815518T
Other languages
English (en)
Other versions
DE69815518T2 (de
Inventor
M Samir Amer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25204013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69815518(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of DE69815518D1 publication Critical patent/DE69815518D1/de
Application granted granted Critical
Publication of DE69815518T2 publication Critical patent/DE69815518T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69815518T 1997-02-28 1998-01-23 S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist Expired - Lifetime DE69815518T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/810,503 US5780487A (en) 1995-08-07 1997-02-28 S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide
US810503 1997-02-28
PCT/US1998/001304 WO1998038165A1 (en) 1997-02-28 1998-01-23 S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide as a 5-ht2 receptor antagonist

Publications (2)

Publication Number Publication Date
DE69815518D1 true DE69815518D1 (en) 2003-07-17
DE69815518T2 DE69815518T2 (de) 2004-04-22

Family

ID=25204013

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69815518T Expired - Lifetime DE69815518T2 (de) 1997-02-28 1998-01-23 S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist

Country Status (11)

Country Link
US (1) US5780487A (de)
EP (1) EP0973741B1 (de)
JP (1) JP3492378B2 (de)
KR (1) KR20000075696A (de)
AT (1) ATE242765T1 (de)
AU (1) AU750603B2 (de)
CA (1) CA2282840C (de)
DE (1) DE69815518T2 (de)
ES (1) ES2201440T3 (de)
NO (1) NO318443B1 (de)
WO (1) WO1998038165A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10036802A1 (de) * 2000-07-28 2002-02-07 Tesa Ag Haftklebemassen auf Basis von Blockcopolymeren der Struktur P(A)-P(B)-P(A)
PL373484A1 (en) * 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7600626B2 (en) * 2002-06-13 2009-10-13 Cummins-Allison Corp. Currency processing and strapping systems and methods
DE10358525A1 (de) 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
BRPI0618766A2 (pt) * 2005-11-17 2011-09-13 Novartis Ag compostos e a fabricação dos mesmos
EP1994001A2 (de) * 2005-11-17 2008-11-26 Novartis AG Benzeneszkfibat-salze und ihre verwendung als zwischenprodukte zur synthese von 2-[2-(1-alkyl-2-piperidyl)ethyl]-cinnamaniliden
MX2011004284A (es) * 2008-10-22 2011-06-21 Sam Amer & Co Inc Metodo para tratar la hipertension arterial pulmonar.
WO2012026914A1 (en) * 2010-08-23 2012-03-01 Sam Amer & Co., Inc. Methods and compositions for treating internal and external hemorrhoids
WO2013070236A1 (en) * 2011-11-11 2013-05-16 Ventrus Biosciences, Inc. Methods and compositions for treating hemorrhoids while providing local anesthetic and anti-inflammatory effects
CN102924374B (zh) * 2012-02-15 2014-04-16 湖北欣瑞康医药科技有限公司 喹啉-4-羧酸衍生物的制备方法
CH706161A1 (de) 2012-03-15 2013-10-15 Oti Greentech Group Ag Ölrückgewinnung.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064254A (en) * 1971-03-03 1977-12-20 Mead Johnson & Company Substituted piperidines therapeutic process and compositions
US4000143A (en) * 1971-03-03 1976-12-28 Mead Johnson & Company Substituted piperidines
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
GB9402688D0 (en) * 1994-02-11 1994-04-06 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
ATE242765T1 (de) 2003-06-15
EP0973741B1 (de) 2003-06-11
AU6037798A (en) 1998-09-18
CA2282840A1 (en) 1998-09-03
US5780487A (en) 1998-07-14
JP2001527521A (ja) 2001-12-25
KR20000075696A (ko) 2000-12-26
NO318443B1 (no) 2005-03-21
CA2282840C (en) 2006-04-11
DE69815518T2 (de) 2004-04-22
NO994181L (no) 1999-10-27
ES2201440T3 (es) 2004-03-16
WO1998038165A1 (en) 1998-09-03
JP3492378B2 (ja) 2004-02-03
EP0973741A1 (de) 2000-01-26
AU750603B2 (en) 2002-07-25
NO994181D0 (no) 1999-08-27

Similar Documents

Publication Publication Date Title
DE69815518D1 (en) S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
SE9503924D0 (sv) Novel opioid peptides
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
DE69616749T2 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
DK0735868T3 (da) Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul
IL111127A (en) Short-acting calcium antagonist dihydropyridines process for their preparation and pharmaceutical compositions containing them
GT199700037A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
IT1250049B (it) Composti triciclici.
CA2459470A1 (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use
RU94046107A (ru) Замещенные производные 2 бета - морфолинандростана, способ их получения, фармакомпозиция, содержащая их
ES2102994T3 (es) Derivados de benzisotiazolinona-1-dioxido como inhibidores de elastasa.
CA2360300A1 (en) A transdermal composition of an antivomiting agent and a preparation containing the same
GEP20012389B (en) Benzoxazinone Dopamine D4 Receptor Antagonists, Pharmaceutical Composition Containing the Same and Method for Treatment of Psychosis or Schizophrenia
MY111055A (en) Pharmaceutical composition and process for the preparation thereof
GEP19981163B (en) Neuromuscular blocking agent, its production, pharmaceutical compound and process for providing the neuromuscular blocking agents
ATE57188T1 (de) Pharmazeutische peptide, ihre herstellung und verwendung sowie zwischenprodukte.
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
EA199800013A1 (ru) Способы минимизации остеопороза
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
TW325394B (en) Fungicidal mixtures
AU3623399A (en) Use of benzofuroxan derivatives in treating angina pectoris
MX9702253A (es) Nuevos estrenos para inducir efectos hipotalamicos
DK0991409T3 (da) Farmaceutiske tiagabinindeholdende præparater med reguleret frigivelse
TR200000154T2 (tr) 2,4,4-Trisübstitüe-1,3-Dioksolan mantar önleyiciler.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition